Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones
Psyence Biomedical Ltd. (PBM)
Company Research
Source: GlobeNewswire
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today issued the following letter to shareholders. To my fellow shareholders: Having recently commenced trading on the Nasdaq stock exchange under the ticker “PBM,” following the completion of our business combination with Newcourt Acquisition Corp., I am happy to write to update you on our recent progress and upcoming milestones. Our merger with Newcourt and subsequent listing on Nasdaq confers numerous benefits to our company. These include expanded access to capital to fund our development programs and the opportunity to share the Psyence story more broadly and garner support from more sophisticated long-term institutional life sciences investors to further enhance our value. Recall that we are exploring the therapeutic potential of nature-derived psilocybin (the n
Show less
Read more
Impact Snapshot
Event Time:
PBM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBM alerts
High impacting Psyence Biomedical Ltd. news events
Weekly update
A roundup of the hottest topics
PBM
News
- Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)GlobeNewswire
- Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin TrialGlobeNewswire
- Psyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin TrialGlobeNewswire
- Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical BusinessGlobeNewswire
- Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic PsilocybinGlobeNewswire